1,5-dihydro-pyrrolo[2,3-d]pyridazin-4-one | 19880-37-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1,5-dihydro-pyrrolo[2,3-d]pyridazin-4-one
• 英文别名: 1,5-Dihydropyrrolo[2,3-D]pyridazin-4-one；1,5-dihydropyrrolo[2,3-d]pyridazin-4-one
• CAS: 19880-37-6
• 化学式: C₆H₅N₃O
• 分子量: 135.125
• InChiKey: NUNJYIYITJAZSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Diazaindole-dicarbonyl-piperazinyl antiviral agents
  申请人：Bender A. John

  公开号：US20050124623A1

  公开（公告）日：2005-06-09

  The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula I wherein: Q is selected from the group consisting of — may represent a bond; T is —C(O)— or —CH(CN)—; and —Y— is selected from the group consisting of compositions thereof and their use for treating HIV infection.

  这项发明包括通式I的替代二氮杂吲哚-二羰基-哌嗪基衍生物，其中：Q选自由一组，可以表示成键；T为—C(O)—或—CH(CN)—；以及—Y—选自由一组，包括其组成物及其用于治疗HIV感染的用途。
• [EN] IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS<br/>[FR] DÉRIVÉS D'IMIDAZOPYRAZINOL POUR LE TRAITEMENT DES CANCERS
  申请人：OSI PHARM INC

  公开号：WO2009091939A1

  公开（公告）日：2009-07-23

  Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-IR enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  化合物的结构式（I）及其药用盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1在此处定义，抑制IGF-IR酶，可用于治疗和/或预防高增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病以及中枢神经系统疾病和病况。
• DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS
  申请人：Bender John A.

  公开号：US20080125439A1

  公开（公告）日：2008-05-29

  The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula I wherein: Q is selected from the group consisting of -- may represent a bond; T is —C(O)— or —CH(CN)—; and —Y— is selected from the group consisting of compositions thereof and their use for treating HIV infection.

  该发明涉及一种一般式I的取代的二氮杂吲哌唑-二羧酰基-哌嗪基衍生物，其中：Q选自由以下组成的群：-可能代表键；T为-C（O）-或-CH（CN）-；和-Y-选自由以下组成的群：其组成物及其用于治疗HIV感染的用途。
• IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS
  申请人：Mulvihill Mark J.

  公开号：US20110046144A1

  公开（公告）日：2011-02-24

  Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit the IGF-IR enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  化合物公式(I)及其药学上可接受的盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1的定义如下，能够抑制IGF-IR酶并用于治疗和/或预防过度增殖性疾病，如癌症、炎症、银屑病、过敏/哮喘、免疫系统疾病和疾病以及中枢神经系统疾病和疾病状态。
• Heterocyclic compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0733633B1

  公开（公告）日：2003-05-28